Stephan Faderl

Author PubWeight™ 6.90^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia.	Br J Haematol	2011	1.07
2	Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma.	Clin Cancer Res	2004	0.92
3	Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes.	Leuk Res	2005	0.86
4	Retrospective comparison of clofarabine versus fludarabine in combination with high-dose cytarabine with or without granulocyte colony-stimulating factor as salvage therapies for acute myeloid leukemia.	Haematologica	2012	0.83
5	Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survival.	Br J Haematol	2002	0.82
6	Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia.	Leuk Res	2003	0.81
7	Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia.	Cancer Chemother Pharmacol	2002	0.81
8	Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia.	Clin Cancer Res	2002	0.75